Correspondence 0001193125-26-288417 from Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: June 29, 2026 · CIK: 0001645460 · Accession: 0001193125-26-288417
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296896
Letter
Re: Cue Biopharma, Inc. Registration Statement on Form S-3 (File No. 333-296896) Request for Acceleration of Effective Date Tim Buchmiller: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-296896) (the “ Registration Statement ”) to become effective on July 1, 2026, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Courtney M.W. Tygesson and Sara Semnani of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Courtney M.W. Tygesson of Cooley LLP, counsel to the Registrant, at (312) 881-6680 or ctygesson@cooley.com, or in her absence, Sara Semnani at (858) 550-6227or ssemnani@cooley.com. [Signature page follows]
C UE B IOPHARMA , I NC . 40 Guest Street Boston, Massachusetts 02135 June 29, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller
Very truly yours,
Cue Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP C UE B IOPHARMA , I NC . 40 Guest Street Boston, Massachusetts 02135 June 29, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Cue Biopharma, Inc. Registration Statement on Form S-3 (File No. 333-296896) Request for Acceleration of Effective Date Tim Buchmiller: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-296896) (the “ Registration Statement ”) to become effective on July 1, 2026, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Courtney M.W. Tygesson and Sara Semnani of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Courtney M.W. Tygesson of Cooley LLP, counsel to the Registrant, at (312) 881-6680 or ctygesson@cooley.com, or in her absence, Sara Semnani at (858) 550-6227or ssemnani@cooley.com. [Signature page follows] Very truly yours, Cue Biopharma, Inc. By: /s/ Sumita Ray Sumita Ray Chief Legal & Compliance Officer and Corporate Secretary cc: Shao-Lee Lin, Cue Biopharma, Inc. Michael Meluzio, Cue Biopharma, Inc. Divakar Gupta, Cooley LLP Sara Semnani, Cooley LLP Courtney M.W. Tygesson, Cooley LLP Signature Page to Company Acceleration Request – S-3